Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO)

NEW YORK ( TheStreet) -- The ex-dividend date for Meridian Bioscience (Nasdaq: VIVO) is tomorrow, July 28, 2011. Owners of shares as of market close today will be eligible for a dividend of 19 cents per share. At a price of $21.40 as of 9:31 a.m. ET, the dividend yield is 3.4%.

The average volume for Meridian Bioscience has been 243,400 shares per day over the past 30 days. Meridian Bioscience has a market cap of $905 million and is part of the health care sector and drugs industry. Shares are down 6.8% year to date as of the close of trading on Tuesday.

Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. The company has a P/E ratio of 35, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.
  • Practice your dividend trading strategies and win cash in our stock game.

TheStreet Ratings rates Meridian Bioscience as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, growth in earnings per share, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Meridian Bioscience Ratings Report.

See our dividend calendar or top-yielding stocks list.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing